ISSWSH ISSUES IMPORTANT UPDATES FOR HSDD THERAPIES

ISSWSH is pleased to provide the following updates related to therapies for Hypoactive Sexual Desire Disorder or HSDD. The FDA has updated prescribing information for flibanserin, removed the REMS certification requirement for prescribers and pharmacists, and updated safety information related to the alcohol contraindication. In addition, bremelanotide has now been approved for treatment of HSDD. Please see the attached news release related to these two therapies for more specific information and references.

News Release

Save The Date

ISSWSH Fall Course 2023

October 19-22, 2023   136 days left
DoubleTree Resort - Paradise Valley - Scottsdale, AZ
Visit the Course Website

ISSWSH Annual Meeting 2024

February 22-25, 2024   262 days left
Hyatt Regency Long Beach - Long Beach, CA
Visit the Meeting Website

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Us

On Twitter
On Facebook
On Instagram